Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes
Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes

Non-transfusion-dependent β-thalassemia: A disease of clinical paradoxes

Blood Rev. 2026 Aug 27:101430. doi: 10.1016/j.blre.2026.101430. Online ahead of print.

ABSTRACT

Non-transfusion-dependent β-thalassemia (NTDT) was historically regarded as a relatively mild form of thalassemia because patients survive without regular transfusion therapy. However, growing evidence has challenged this perception and uncovered substantial morbidity and premature mortality driven by chronic anemia, iron overload, and hypercoagulability. This review examines three major clinical paradoxes that have reshaped the understanding of NTDT: the anemia paradox, whereby transfusion-independent patients may actually benefit from anemia correction; the iron overload paradox, characterized by clinically significant iron accumulation despite minimal or no transfusion exposure; and the hypercoagulability paradox, whereby chronic anemia coexists with a prothrombotic state. These evolving concepts have transformed NTDT from a condition traditionally managed through observation into a disease requiring proactive, risk-based intervention.

PMID:42674914 | DOI:10.1016/j.blre.2026.101430